The facade of Moderna, Inc. headquarters is seen, Tuesday, Dec. 15, 2020, in Cambridge, Mass.
The Food and Drug Administration said that a second potential COVID-19 vaccine, developed by Moderna, appears safe and highly effective, bringing it to the cusp of U.S. authorization.
(AP Photo/Elise Amendola)AMSTERDAM – The European Union’s medicines agency announced Thursday that it has moved forward a meeting to consider authorizing a coronavirus vaccine made by Moderna for use in the 27-nation bloc.
The Amsterdam-based agency, which is meeting Monday to consider authorizing a vaccine made by Pfizer Inc. and German company BioNTech for use in the EU, had scheduled a meeting to discuss the Moderna vaccine on Jan. 12, but that has now been brought forward to Jan. 6.
The decision came after Moderna sent that last package of data on the vaccine needed for the agency to assess it for the EU market, the EMA said.